Project Grant R21HL168430
Award Date
9/1/24
Completion Date
6/30/26
Dollars Obligated
$231K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Detroit, MI 48202, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,530 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Spinhance LLC, a for-profit limited liability company located in Rydal, Pennsylvania. The grant aims to design, build, and evaluate a novel cardiopulmonary imaging device for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129. This system is intended to support a new paradigm for...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $786,139 to The Trustees of the University of Pennsylvania to develop a technique for dynamically imaging lung function in free-breathing subjects using hyperpolarized 129Xe MRI. The goal is to enable a more physiologically relevant assessment of lung function, especially in patient populations with poor breath-hold tolerance. The project...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $742,810 to the University of Virginia to develop hyperpolarized gas MRI (HGMRI) signatures for detecting and monitoring acute cellular rejection in lung transplant recipients. The 5-year project aims to correlate HGMRI signatures with tissue pathology, treatment response, and single-cell RNA-sequencing data to enhance early...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This Project Grant award of $1,331,984.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to develop new lung quantitative ultrasound (LQUS) metrics for monitoring pulmonary edema due to heart failure and idiopathic pulmonary fibrosis. The primary awardee, North Carolina State University, will work to mitigate chest-wall effects, optimize data acquisition, and apply LQUS methods in human patients with heart failure and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $191,913 to The University of Texas MD Anderson Cancer Center to research the use of hyperpolarized xenon-129 MRI as a predictive biomarker for mitigating radiation-induced lung injury (RILI) in lung cancer patients undergoing radiotherapy. The 5-year project aims to: 1) determine the effect of baseline lung function, tumor location, and radiation modality on...
The federal Project Grant award R01HL175892, funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate new technology for accurate, rapid, point-of-care, and high-frequency blood gas analysis. The $735,939 award supports two key objectives: 1) creating a miniaturized and automated device that attaches to an arterial catheter to enable direct sampling and immediate blood gas analysis at the bedside,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,614,450.00 to The Regents of the University of California, San Francisco to develop and translate hyperpolarized 13C-pyruvate MRI technology for evaluating metabolic remodeling in heart disease. The key goals are to: Develop hyperpolarized 13C-pyruvate MRI methods to assess metabolic flexibility and glycolysis-glucose oxidation coupling under different...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $260,586 to the University of Wisconsin-Madison over a 5-year period starting September 1, 2024. The objective is to develop and optimize a novel positron emission tomography (PET) probe that can monitor extracellular matrix deposition and disease activity in idiopathic pulmonary fibrosis (IPF), a fatal lung disease characterized by...
This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...